FluMist Sales Falling Short, Survey Finds: Md. Company Increased Vaccine Production at U.S. Government's Request (Post, Jan. 6, 2005)

MedImmune Forms Research Partnership: Collaboration With Medarex to Focus On Autoimmune Disease Treatments (Post, Nov. 24, 2004)

Spray Flu Vaccine Comes at a Trickle: Despite New Doses, FluMist Could Be as Elusive as Shots (Post, Nov. 13, 2004)

MedImmune Has A Higher Loss In Third Quarter (Post, Oct. 22, 2004)

MedImmune to Produce Additional Flu Vaccine: HHS Says U.S. Supply Could Hit 61 Million Doses (Post, Oct. 22, 2004)

MedImmune Tapped For More Flu Vaccine: CDC Requests Increase in Production (Post, Oct. 6, 2004)

Washington Investing
Insider Traders Who Push Too Far Can Pay Dearly (Post, Sept. 27, 2004)

MedImmune CEO Speaks Finance And Science (Post, Sept. 27, 2004)

Plea Due in MedImmune Stock Case (Post, Sept. 17, 2004)

MedImmune Ends Some Vitaxin Testing: Advanced Tests for Arthritis Treatment Halted; Cancer Research Continues (Post, Aug. 31, 2004)

MedImmune Posts Loss in 2nd Quarter (Post, July 23, 2004)

MedImmune To Try New FluMist Tactic (Post, June 16, 2004)

MedImmune Cuts Wyeth Tie: Company Will Promote FluMist Vaccine on Its Own (Post, April 28, 2004)

MedImmune, Wyeth End FluMist Partnership (Post, April 27, 2004)

MedImmune Profit Virtually Unchanged: FluMist Flop Hobbles Biotech Firm (Post, April 22, 2004)

MedImmune Looks to Boost FluMist Sales: Company Hopes New Version Will Fix Problems Faced by Nasal Vaccine in Its Debut (Post, March 2, 2004)

No Healthy Profit From FluMist: MedImmune Weighs Options as Quarterly Earnings Drop 9 Percent (Post, Jan. 30, 2004)

The Vaccine That Missed: Sales of Pricey FluMist Disappoint Wyeth, MedImmune (Post, Jan. 23, 2004)

FluMist Offered Free to Public Health Agencies (Post, Jan. 21, 2004)